EMAIL THIS PAGE TO A FRIEND

Science (New York, N.Y.)

Subthalamic GAD gene therapy in a Parkinson's disease rat model.


PMID 12376704

Abstract

The motor abnormalities of Parkinson's disease (PD) are caused by alterations in basal ganglia network activity, including disinhibition of the subthalamic nucleus (STN), and excessive activity of the major output nuclei. Using adeno-associated viral vector-mediated somatic cell gene transfer, we expressed glutamic acid decarboxylase (GAD), the enzyme that catalyzes synthesis of the neurotransmitter GABA, in excitatory glutamatergic neurons of the STN in rats. The transduced neurons, when driven by electrical stimulation, produced mixed inhibitory responses associated with GABA release. This phenotypic shift resulted in strong neuroprotection of nigral dopamine neurons and rescue of the parkinsonian behavioral phenotype. This strategy suggests that there is plasticity between excitatory and inhibitory neurotransmission in the mammalian brain that could be exploited for therapeutic benefit.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

G1001
D-Glutamic acid, ≥99% (TLC)
C5H9NO4